

Edgar Filing: THERMOGENESIS CORP - Form 8-K

THERMOGENESIS CORP  
Form 8-K  
January 17, 2006

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 16, 2006

THERMOGENESIS CORP.  
(Exact name of registrant as specified in its charter)

Delaware -----	0-16375 -----	94-3018487 -----
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification No.)

2711 Citrus Road  
Rancho Cordova, California 95742  
-----  
(Address and telephone number of principal executive  
offices) (Zip Code)

(916) 858-5100  
-----  
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Section 8 - Other Events  
-----

Item 8.01 Other Events.

Edgar Filing: THERMOGENESIS CORP - Form 8-K

On January 3, 2006, ThermoGenesis Corp. (the "Company") announced that the Center for Biologics Evaluation and Research ("CBER") notified the Company that it was reviewing the Company's pre-market application ("PMA") for its CryoSeal FS System ("CryoSeal"). The PMA submission was based on clinical results from a Phase III trial evaluating the safety and efficacy of CryoSeal as an adjunct to hemostasis in liver resection surgery against the control, INSTAT(R), a collagen absorbable hemostat. If approved, CryoSeal would be the only fibrin sealant on the market that is produced from the patient's own blood, and an alternative to conventional fibrin sealants that are derived from bovine tissue or pooled human blood.

Although CBER acknowledged that it was reviewing the Company's PMA for CryoSeal, no assurance can be given that CBER will not require further testing and clinical data, or that CryoSeal will ultimately be approved by the FDA to be marketed in the United States. If further testing and clinical studies are required, there can be no assurance that the clinical studies can be successfully completed within the Company's expected time frame and budget, or that such studies will provide required findings for approval. If the Company is unable to receive FDA approval for CryoSeal, the Company's business, financial condition and results of operations could be adversely affected.

Additional information can be found on the press release attached as Exhibit 99.

Section 9 - Financial Statements and Exhibits  
-----

Item 9.01 Financial Statements and Exhibits.

Exhibit No. -----	Exhibit Description -----
99	Press Release dated January 3, 2006 titled "Thermogenesis Corp. Files PMA to Market CryoSeal(R) Fibrin Sealant (FS) in Liver Resection Surgeries"

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

THERMOGENESIS CORP.,  
a Delaware Corporation

Dated: January 16, 2006

/s/ Matthew Plavan  
-----

Matthew Plavan,  
Chief Financial Officer

Edgar Filing: THERMOGENESIS CORP - Form 8-K

EXHIBIT INDEX

Exhibit No.	Description
-----	-----
99	Press Release dated January 3, 2006 titled "Thermogenesis Corp. Files PMA to Market CryoSeal(R) Fibrin Sealant (FS) in Liver Resection Surgeries"